Endothelial Integrin Alpha-V Beta-3 (Clone 17.16) Aptamer Details
ID# 7613
Structure
Chemistry
RNA
Target
Alpha-V Beta-3
Category
Protein
Affinity (Kd)
N/A nM
Length
37
Aptazyme
No
Sequence (3-char table code)
G
A
C
U/T
5'-rUprUprCprAprAprCprGprCprUprGprUprGprAprAprGprGprGprCprUprUprAprUprAprCprGprAprGprCprGprGprAprUprUprAprCprCprCp-3'
Molecular Weight: 11855.18
Extinction Coefficient: 364200
Binding Conditions / Buffer
Washed with PBS and 0.9 mM CaCl2, 0.5 mM MgCl2, 2.67 mM KCl, 1.47 mM KH2PO4, 135 mM NaCl, and 8 mM Na2.
Binding Temp: 37°C
Refolding Protocol
If the oligo is a known aptamer sequence: For binding studies, perform a refolding protocol to ensure proper function (i.e. binding to antigen or target). Refer to the aptamer reference source for the appropriate refolding parameters and binding conditions. Note: it is unknown whether aptamer functions properly without refolding.
Note: Information on this aptamer oligo was obtained from the literature and hasn't been validated by Aptagen.
Reference
Brunette et al. "RNA Aptamer Therapy for Vaso-Occlusion in Sickle Cell Disease." Nucleic Acids Therapeutics, 21(2011): 275-283. Mi et al. "Targeted inhibition of av??3 integrin with an RNA aptamer impairs endothelial cell growth and survival." Biochemical and Biophysical Research Communications, 338(2005): 956-963.
Request a Quote
Have your aptamer oligo synthesized by Aptagen.
